fda warning letters compounded semaglutide tirzepatide 2025 July 29, 2024: issued new alert about – Partnership for Safe Medicines New project announcement: HHS‑OIG is

GLP-1R agonists effects on cardiovascular events The first pieces of evidence of the potential clinical benefit of GLP-1 agonists have emerged recently, pointing to a decrease of major adverse cardiovascular and cerebrovascular events (MACCE) including stroke, MI, cardiac mortality, acute coronary syndrome, and revascularization procedures

[DOI] [PubMed] [Google Scholar] 107.Sager M

13) Addictions Various drugs of abuse (such as cocaine and methamphetamines), as well as alcohol, increase the production of reactive oxygen species

Short-Term Use for Specific Goals Some patients may use GLP-1 medications for a shorter period to achieve specific weight loss goals, such as losing a certain amount of weight for an event or to improve a health condition (for example, reducing blood pressure)